Skip to main content

Chaysavanh Manichanh

Institutions of which they are part

Head of group
Microbiome Research
Vall Hebron Institut de Recerca

Chaysavanh Manichanh

Institutions of which they are part

Head of group
Microbiome Research
Vall Hebron Institut de Recerca

Research lines

The Human Microbiome

The Microbiome Research Group seeks to investigate the role of the microbiota in health and disease. Its secondary objectives include:

1. Role of the microbiota in health and disease

2. Tools to characterize the microbiome structure and function

3. Micro-biomarkers for diagnosis and prognosis

4. Fecal microbiota transplantation as a therapeutic strategy

5. Impact of diet on the gut microbial ecosystem


IP: Chaysavanh Manichanh

Gut Microbiota

The human microbiome is the collective genomes of all microorganisms living at the multiple sites of the human body (oral cavity, skin, nasal cavity, gastrointestinal tract (GI) and vagina). Human (Homo sapiens) and their commensal microorganisms have evolved together over the last 200,000 years and have become dependent on one another. Interaction between humans and their symbiotic bacteria is essential to many aspects of normal ‘mammalian’ physiology, ranging from metabolic activity to immune homeostasis, and ecological or genetic changes that disturb this mutualism can result in disease. It reflects the evolutionary selection pressures acting at both the levels of the host and the microbial cells and has a direct profound impact on human health. This line of research aims at understanding the role of the gut microbiome in intestinal disorders using ‘omics approaches.


Our research group proposes a service-collaboration in Microbiome analysis.

You can find further information on our prices at the following URL.

IP: Chaysavanh Manichanh

Projects

El déficit de CFTR facilita la carcinogénesis pancreática y potencia el crecimiento, la agresividad tumoral y las metástasis

IP: Chaysavanh Manichanh
Collaborators: Laura Campderros Traver, Judit Álvarez González
Funding agency: Instituto de Salud Carlos III
Funding: 95000
Reference: CD22/00177
Duration: 01/03/2023 - 28/02/2025

Fisiologia i fisiopatologia digestiva

IP: Chaysavanh Manichanh
Collaborators: Itxarone Izaskun Bilbao Aguirre, Zaida Soler Luque, Jordi Barquinero Mañez, Oscar Segarra Canton, Gerard Serrano Gomez, Cristina Dopazo Taboada, Rocío Piñera Moreno
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00459
Duration: 01/01/2022 - 31/12/2024

Evaluate the effect of diet on the gut microbial community

IP: Chaysavanh Manichanh
Collaborators: Zaida Soler Luque, Judit Álvarez González
Funding agency: Instituto de Salud Carlos III
Funding: 119567
Reference: FI21/00262
Duration: 01/01/2022 - 31/12/2025

Inflammatory Bowel Disease and Microbiome: Diagnosis and prediction of disease activity from the lab to the patients

IP: Chaysavanh Manichanh
Collaborators: Luis Fernando Mayorga Ayala
Funding agency: Instituto de Salud Carlos III
Funding: 65000
Reference: CM21/00198
Duration: 01/01/2022 - 24/11/2022

Related news

This work sets the basis for future research aimed at a deeper understanding of the microbiota and the effect of nutrition.

These are the results of a study published in Nature Communications and led by the Vall d'Hebron Research Institute (VHIR), the University of Lleida (UdL) and the Biomedical Research Institute of Lleida (IRBLleida).

The composition of gut microbiota is unique, like our fingerprints.

Related professionals

Valeria Rizzuto

Valeria Rizzuto

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Emanuela Greco

Emanuela Greco

Predoctoral researcher
Read more
Jose Cabral Jamba

Jose Cabral Jamba

Administrative
IT / Information Systems
Digital Transformation and Quality Area
Read more
Sebastián  Sandoval  Moreno

Sebastián Sandoval Moreno

Predoctoral researcher
Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.